VBS
0.14
89.2%
AUK
0.003
-25%
RKB
0.006
50%
SPX
0.003
-25%
WBE
0.006
50%
COB
0.165
-21.4%
BMG
0.019
46.2%
PKY
0.015
-21.1%
FCT
0.017
41.7%
CAE
0.054
-20.6%
NYR
0.45
38.5%
CTN
0.004
-20%
THR
0.018
38.5%
FBR
0.004
-20%
CCO
0.004
33.3%
RFT
0.004
-20%
DTZ
0.063
28.6%
RML
0.08
-20%
1AD
0.005
25%
ASQ
0.021
-19.2%
CAV
0.005
25%
AAJ
0.023
-17.9%
MMR
0.005
25%
CLA
0.01
-16.7%
NWM
0.015
25%
ENT
0.005
-16.7%
TMX
0.005
25%
TYX
0.005
-16.7%
YAR
0.015
25%
LMS
0.58
-16.5%
ELT
0.28
24.4%
SNS
0.105
-16%
AUG
0.055
22.2%
INF
0.017
-15%
FMR
0.39
21.9%
HHR
0.006
-14.3%
WYX
0.075
21%
LPM
0.12
-14.3%
ROG
0.006
20%
WSR
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts